Ten-Year Outcomes after CAR T-Cell Therapy for B-Cell Lymphomas.

What was studied

This study followed 38 patients with relapsed or refractory B-cell lymphoma for 10 years. Anti-CD19 CAR T-cell therapy is a standard treatment, but long-term results are uncertain. Of these, 14 had follicular lymphoma and 24 had large B-cell lymphoma. All got a single infusion of CTL019 (now tisagenlecleucel). Lymphoma-free survival ran from infusion to relapse or lymphoma-related death. The data cutoff was October 1, 2025.

What they found

Median follow-up was 10.1 years. No relapses occurred beyond 5.4 years. Lymphoma-free survival at 10 years was 32 in large B-cell disease. It was 47 in follicular lymphoma. Overall survival at 10 years was 17 and 50 in the same order. Neutropenia of grade 2 or 3 persisted in 2 patients. No late anemia or low platelets were seen. Another primary cancer arose in 9 patients. Higher CAR-transgene persistence appeared linked to long-term response.

What it means for patients

The team says a single infusion led to decade-long remissions in heavily pretreated patients. This was seen in a part of those with large B-cell lymphoma. A larger part of those with follicular lymphoma had such remissions.

Why it is not certain yet

Only 38 patients were studied. The confidence intervals around the 10-year rates were wide. The study had no comparison group. The word appeared marks the link to CAR-transgene persistence.

Source

Ten-Year Outcomes after CAR T-Cell Therapy for B-Cell Lymphomas.

We restate facts from the source record in our own words. The original wording belongs to its publisher.